
Erin A Mcclure

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2272115/publications.pdf Version: 2024-02-01



FRIN A MCCLUPE

#	Article	IF	CITATIONS
1	A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth. Drug and Alcohol Dependence, 2022, 232, 109311.	1.6	23
2	Daily Cannabis Use Is a Barrier to Tobacco Cessation Among Tobacco Quitline Callers at 7-Month Follow-up. Nicotine and Tobacco Research, 2022, 24, 1684-1688.	1.4	6
3	Characterization of Salivary Progesterone in Female Smokers. Nicotine and Tobacco Research, 2022, 24, 1829-1833.	1.4	2
4	Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addiction Biology, 2021, 26, e12918.	1.4	9
5	Mobile, Remote, and Individual Focused: Comparing Breath Carbon Monoxide Readings and Abstinence Between Smartphone-Enabled and Stand-Alone Monitors. Nicotine and Tobacco Research, 2021, 23, 741-747.	1.4	13
6	Unknown populationâ€level harms of cannabis and tobacco coâ€use: if you don't measure it, you can't manage it. Addiction, 2021, 116, 1622-1630.	1.7	43
7	Accurate and sufficient measurement of cannabis and tobacco coâ€use: agreement, consensus and the path forward. Addiction, 2021, 116, 1636-1637.	1.7	3
8	Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis. Drug and Alcohol Dependence, 2021, 221, 108570.	1.6	7
9	Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug and Alcohol Dependence, 2021, 225, 108815.	1.6	7
10	Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine and Tobacco Research, 2020, 22, 81-88.	1.4	19
11	<i>N</i> â€acetylcysteine yields sexâ€specific efficacy for cueâ€induced reinstatement of nicotine seeking. Addiction Biology, 2020, 25, e12711.	1.4	23
12	Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology, 2020, 237, 479-490.	1.5	14
13	Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine and Tobacco Research, 2020, 22, 1374-1382.	1.4	23
14	The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology, 2020, 237, 543-555.	1.5	17
15	Treatment Implications Associated With Cannabis and Tobacco Co-use. Current Addiction Reports, 2020, 7, 533-544.	1.6	26
16	Substance use disorders and COVID-19: the role of telehealth in treatment and research. Journal of Social Work Practice in the Addictions, 2020, 20, 248-253.	0.4	18
17	Remote Methods for Conducting Tobacco-Focused Clinical Trials. Nicotine and Tobacco Research, 2020, 22, 2134-2140.	1.4	44
18	Association of Cannabis Use With Intimate Partner Violence Among Couples With Substance Misuse. American Journal on Addictions, 2020, 29, 323-330.	1.3	13

#	Article	IF	CITATIONS
19	Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology, 2020, 120, 104752.	1.3	9
20	Making pharmacotherapy trials for substance use disorder more efficient: Leveraging real-world data capture to maximize power and expedite the medication development pipeline. Drug and Alcohol Dependence, 2020, 209, 107897.	1.6	11
21	Commentary on Guillaumier et al . (2020): Is harm reduction a suitable outcome for historically hardâ€ŧoâ€ŧreat smokers?. Addiction, 2020, 115, 1356-1357.	1.7	0
22	An electronic, smart lighter to measure cigarette smoking: A pilot study to assess feasibility and initial validity. Addictive Behaviors, 2019, 98, 106052.	1.7	18
23	Efficacy and Safety of Varenicline for Adolescent Smoking Cessation. JAMA Pediatrics, 2019, 173, 1146.	3.3	26
24	Methods to reduce the incidence of false negative trial results in substance use treatment research. Current Opinion in Psychology, 2019, 30, 35-41.	2.5	9
25	Pharmacological Treatment of Youth Substance Use Disorders. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 559-572.	0.7	44
26	Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug and Alcohol Dependence, 2019, 198, 105-111.	1.6	11
27	Measuring Within-Individual Cannabis Reduction in Clinical Trials: a Review of the Methodological Challenges. Current Addiction Reports, 2019, 6, 429-436.	1.6	9
28	Chronic treatment with <i>N</i> -acetylcysteine decreases extinction responding and reduces cue-induced nicotine-seeking. Physiological Reports, 2019, 7, e13958.	0.7	22
29	Tobacco and cannabis co-use and interrelatedness among adults. Addictive Behaviors, 2019, 90, 354-361.	1.7	41
30	Clinical Treatment of Addictive Disorders with N-Acetylcysteine. , 2019, , 219-233.		3
31	Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. American Journal of Drug and Alcohol Abuse, 2019, 45, 26-41.	1.1	26
32	Assessing the Digital Divide Among Low-Income Perinatal Women: Opportunities for Provision of Health Information and Counseling. Telemedicine Journal and E-Health, 2019, 25, 48-54.	1.6	12
33	Tobacco and cannabis co-use: Drug substitution, quit interest, and cessation preferences Experimental and Clinical Psychopharmacology, 2019, 27, 265-275.	1.3	38
34	Medical Cannabis Use among Adults in the Southeastern United States. Cannabis (Research Society on) Tj ETQq	0 0 0 grgBT	Qverlock 10
35	The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug and Alcohol Dependence, 2018, 185, 17-22.	1.6	39

36Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid
biomarkers: Evidence from a clinical trial. Drug and Alcohol Dependence, 2018, 182, 1-7.1.630

#	Article	IF	CITATIONS
37	Introduction to the special issue: Utilizing ambulatory assessment to better understand the etiology, maintenance, treatment, and remission of addictive disorders. Addictive Behaviors, 2018, 83, 1-4.	1.7	3
38	A Focused Career Development Program for Women Faculty at an Academic Medical Center. Journal of Women's Health, 2018, 27, 1474-1481.	1.5	7
39	Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug and Alcohol Dependence, 2018, 192, 59-66.	1.6	21
40	Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers. American Journal of Drug and Alcohol Abuse, 2018, 44, 561-570.	1.1	21
41	Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug and Alcohol Dependence, 2017, 176, 14-20.	1.6	11
42	A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence, 2017, 177, 249-257.	1.6	109
43	Attitudes and Interest in Technology-Based Treatment and the Remote Monitoring of Smoking among Adolescents and Emerging Adults. Journal of Smoking Cessation, 2017, 12, 88-98.	0.3	9
44	Tobacco Use Prevalence and Outcomes Among Perinatal Patients Assessed Through an "Opt-out― Cessation and Follow-Up Clinical Program. Maternal and Child Health Journal, 2017, 21, 1790-1797.	0.7	13
45	Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. Journal of Substance Abuse Treatment, 2017, 81, 53-58.	1.5	88
46	Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology, 2017, 234, 427-435.	1.5	19
47	Mobile devices for the remote acquisition of physiological and behavioral biomarkers in psychiatric clinical research. Journal of Psychiatric Research, 2017, 85, 1-14.	1.5	63
48	Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addictive Behaviors, 2017, 65, 74-80.	1.7	11
49	Gender Differences in Internalizing Symptoms and Suicide Risk Among Men and Women Seeking Treatment for Cannabis Use Disorder from Late Adolescence to Middle Adulthood. Journal of Substance Abuse Treatment, 2016, 66, 16-22.	1.5	33
50	Effects of intimate partner violence, PTSD, and alcohol use on cigarette smoking in a nationally representative sample. American Journal on Addictions, 2016, 25, 283-290.	1.3	5
51	Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addictive Behaviors, 2016, 63, 172-177.	1.7	23
52	The use of Technology in Participant Tracking and Study Retention: Lessons Learned from a Clinical Trials Network Study. Substance Abuse, 2015, 36, 420-426.	1.1	25
53	An open-label pilot trial of <i>N</i> -acetylcysteine and varenicline in adult cigarette smokers. American Journal of Drug and Alcohol Abuse, 2015, 41, 52-56.	1.1	34
54	Menstrual Cycle Phase Effects in the Gender Dimorphic Stress Cue Reactivity of Smokers. Nicotine and Tobacco Research, 2015, 17, 607-611.	1.4	12

#	Article	IF	CITATIONS
55	Increasing Progesterone Levels Are Associated With Smoking Abstinence Among Free-Cycling Women Smokers Who Receive Brief Pharmacotherapy. Nicotine and Tobacco Research, 2015, 17, 398-406.	1.4	52
56	Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. Journal of Substance Abuse Treatment, 2015, 53, 39-46.	1.5	19
57	Gender Differences in Responses to Cues Presented in the Natural Environment of Cigarette Smokers. Nicotine and Tobacco Research, 2015, 17, 438-442.	1.4	34
58	An exploratory shortâ€ŧerm doubleâ€blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction, 2015, 110, 1027-1034.	1.7	15
59	Objective and subjective memory ratings in cannabis-dependent adolescents. American Journal on Addictions, 2015, 24, 47-52.	1.3	7
60	The effects of N -Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study. Drug and Alcohol Dependence, 2015, 156, 234-242.	1.6	79
61	Laboratory Validation of Inertial Body Sensors to Detect Cigarette Smoking Arm Movements. Electronics (Switzerland), 2014, 3, 87-110.	1.8	24
62	Internet-Delivered Treatment for Substance Abuse: A Multisite Randomized Controlled Trial. American Journal of Psychiatry, 2014, 171, 683-690.	4.0	203
63	Craving, Cue Reactivity, and Stimulus Control Among Early-Stage Young Smokers: Effects of Smoking Intensity and Gender. Nicotine and Tobacco Research, 2014, 16, 208-215.	1.4	38
64	Characterizing smoking, cessation services, and quit interest across outpatient substance abuse treatment modalities. Journal of Substance Abuse Treatment, 2014, 46, 194-201.	1.5	40
65	Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders. CNS Drugs, 2014, 28, 95-106.	2.7	159
66	Environmental tobacco smoke exposure among smokers and non-smokers receiving outpatient substance abuse treatment. Addictive Behaviors, 2014, 39, 1718-1722.	1.7	7
67	Cigarette smoking during an <i>N</i> -acetylcysteine-assisted cannabis cessation trial in adolescents. American Journal of Drug and Alcohol Abuse, 2014, 40, 285-291.	1.1	29
68	Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemporary Clinical Trials, 2014, 39, 211-223.	0.8	42
69	Smoking topography and abstinence in adult female smokers. Addictive Behaviors, 2013, 38, 2833-2836.	1.7	5
70	Utilization of communication technology by patients enrolled in substance abuse treatment. Drug and Alcohol Dependence, 2013, 129, 145-150.	1.6	82
71	Characteristics of an Outpatient Treatment Sample by Primary Substance of Abuse. Journal of Addiction Medicine, 2013, 7, 363-371.	1.4	13
72	Effects of Varenicline on Abstinence and Smoking Reward Following a Programmed Lapse. Nicotine and Tobacco Research, 2013, 15, 139-148.	1.4	106

#	Article	IF	CITATIONS
73	The Remote Monitoring of Smoking in Adolescents. Adolescent Psychiatry (Hilversum, Netherlands), 2013, 3, 156-162.	0.1	4
74	Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. Contemporary Clinical Trials, 2012, 33, 386-395.	0.8	50
75	Characterizing smoking topography of cannabis in heavy users. Psychopharmacology, 2012, 220, 309-318.	1.5	41
76	D-amphetamine, nicotine, and haloperidol produce similar disruptions in spatial and nonspatial temporal discrimination procedures. Behavioural Pharmacology, 2011, 22, 101-112.	0.8	4
77	DISRUPTIVE EFFECTS OF STIMULUS INTENSITY ON TWO VARIATIONS OF A TEMPORAL DISCRIMINATION PROCEDURE. Journal of the Experimental Analysis of Behavior, 2010, 94, 57-68.	0.8	2
78	Manipulating pre-feed, density of reinforcement, and extinction produces disruption in the Location variation of a temporal discrimination task in pigeons. Behavioural Processes, 2009, 82, 85-89.	0.5	12
79	ABA chronic dosing of D-amphetamine produces differential drug effects in two variants of a temporal discrimination procedure in pigeons. Behavioural Pharmacology, 2009, 20, 705-719.	0.8	3
80	Effects of acute and chronic d-amphetamine on two variations of a temporal discrimination procedure. Behavioural Pharmacology, 2009, 20, 668-672.	0.8	3
81	Effects of amphetamine on differential reinforcement of low rates of responding. Behavioural Pharmacology, 2007, 18, 119-133.	0.8	7
82	Effects of d-amphetamine on the behavior of pigeons exposed to the peak procedure. Behavioural Processes, 2006, 71, 268-285.	0.5	32
83	Effects of D-amphetamine on temporal discrimination in pigeons. Behavioural Pharmacology, 2005, 16, 193-208.	0.8	39